Protein kinase

Stowers scientists find evidence of unintended impacts from anti-cancer drugs

Retrieved on: 
Wednesday, August 23, 2023

KANSAS CITY, Mo., Aug. 23, 2023 /PRNewswire/ -- With around 90% of drugs failing to make it to market, the potential for improving efficiency within the drug development industry is clear. Drugs designed to combat cancers suffer similar rates of failure for many reasons. Now, researchers have revealed one reason why certain anti-cancer compounds can cause unexpected side effects. This research could help guide an understanding of why some drugs show more promise than others, providing a new tool that can be used to identify those drugs and drug candidates.

Key Points: 
  • This research could help guide an understanding of why some drugs show more promise than others, providing a new tool that can be used to identify those drugs and drug candidates.
  • Thus, the team found a way to capitalize on this variation and asked how chemotherapy drugs impact the nucleolus, causing nucleolar stress.
  • "In this study, we not only evaluated how anti-cancer drugs alter the appearance of nucleoli, but also identified categories of drugs that cause distinct nucleolar shapes," said Gerton.
  • Drugs often fail in clinical trials due to excessive and unintended toxicity that can be caused by their off-target effects.

Kanazawa University research: Experiments provide insights into the molecular mechanism for memory and learning

Retrieved on: 
Monday, July 3, 2023

The strength of these connections varies – for instance strengthening or weakening depending on the signals received and how.

Key Points: 
  • The strength of these connections varies – for instance strengthening or weakening depending on the signals received and how.
  • This synaptic 'plasticity' underlies learning and memory, and the Ca2+/calmodulin-dependent protein kinase II (CaMKII) is known to play a key role.
  • CaMKII is common to a vast range of species from mammals like rats to older, non-mammalian species like the roundworms (C. elegans) and hydra.
  • The type two Ca2+/calmodulin-dependent protein kinases are multifunctional and are involved in neurotransmitter secretion, transcription factor regulation, and glycogen metabolism.

Kanazawa University research: Experiments provide insights into the molecular mechanism for memory and learning

Retrieved on: 
Monday, July 3, 2023

The strength of these connections varies – for instance strengthening or weakening depending on the signals received and how.

Key Points: 
  • The strength of these connections varies – for instance strengthening or weakening depending on the signals received and how.
  • This synaptic 'plasticity' underlies learning and memory, and the Ca2+/calmodulin-dependent protein kinase II (CaMKII) is known to play a key role.
  • CaMKII is common to a vast range of species from mammals like rats to older, non-mammalian species like the roundworms (C. elegans) and hydra.
  • The type two Ca2+/calmodulin-dependent protein kinases are multifunctional and are involved in neurotransmitter secretion, transcription factor regulation, and glycogen metabolism.

Repare Therapeutics to Host Conference Call and Webcast to Discuss Initial RP-6306 Monotherapy Data from Phase 1 MYTHIC Clinical Trial and Early Combination Trials Insights

Retrieved on: 
Friday, June 2, 2023

Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced it will host a conference call and live webcast to present initial monotherapy data from its Phase 1 MYTHIC clinical trial evaluating RP-6306, as well as to provide early insights on ongoing combination trials, on Wednesday, June 7, 2023 at 4:30 p.m. Eastern Time.

Key Points: 
  • Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced it will host a conference call and live webcast to present initial monotherapy data from its Phase 1 MYTHIC clinical trial evaluating RP-6306, as well as to provide early insights on ongoing combination trials, on Wednesday, June 7, 2023 at 4:30 p.m. Eastern Time.
  • RP-6306 is a first-in-class, oral PKMYT1 (Protein Kinase Membrane-associated tyrosine- and threonine- specific cdc-2 inhibitory kinase) synthetic lethal inhibitor in clinical development for the treatment of molecularly selected advanced solid tumors.
  • Conference Call and Webcast Details:
    To access the call, please dial (877) 870-4263 (U.S. and Canada) or (412) 317-0790 (international) at least 10 minutes prior to the start time and ask to be joined to the Repare Therapeutics call.
  • A live video webcast will be available in the Investor section of the Company’s website at https://ir.reparerx.com/news-and-events/events .

Pfizer Presents Scientific Advancements from its Leading Oncology Portfolio at ASCO 2023 Annual Meeting

Retrieved on: 
Thursday, May 25, 2023

Pfizer Inc. (NYSE: PFE) will present data across its Oncology portfolio and growing pipeline, covering multiple tumor types and novel mechanisms of action at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago from June 2 through June 6.

Key Points: 
  • Pfizer Inc. (NYSE: PFE) will present data across its Oncology portfolio and growing pipeline, covering multiple tumor types and novel mechanisms of action at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago from June 2 through June 6.
  • With the recently announced proposed acquisition of Seagen*, a leader in antibody-drug conjugate technology, Pfizer is further accelerating its fight against cancer to deliver the next generation of Oncology breakthroughs.
  • “Placing patients at the center of everything we do is a critical component of advancing cutting-edge science and improving outcomes for patients,” said Dany Habr, M.D., Oncology Chief Medical Affairs Officer, Pfizer.
  • **Pfizer has exclusive rights to BRAFTOVI and MEKTOVI in the U.S., Canada, and all countries in the Latin American, African, and Middle Eastern regions.

New Data at AACR Showcase Reaction Biology's Innovative Approach to Oncology Drug Discovery Services

Retrieved on: 
Friday, April 8, 2022

MALVERN, Pa., April 8, 2022 /PRNewswire/ -- Reaction Biology ("Reaction" or the "Company"), an industry- leading provider of drug discovery services, today announced that twelve abstracts highlighting data from the Company's oncology drug discovery services platform will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2022, held April 8-13, 2022, in New Orleans, Louisiana.

Key Points: 
  • "At AACR 2022, we look forward to showcasing data from our comprehensive suite of innovative drug discovery services that continue to support our clients in their oncology research goals," said Haiching Ma, Ph.D., Chief Scientific Officer of Reaction Biology.
  • "With these data, we continue to build upon our capabilities as a world leader and partner in drug discovery."
  • Reaction will present data from a number of new and enhanced assays and other drug discovery services in oncology.
  • "These data at AACR represent the breadth and depth of Reaction Biology's pre-clinical research services in oncology and underscore why we are a preferred global partner in the area of drug discovery."

Incyclix Bio Announces $30 Million Series B Financing Led by Boxer Capital

Retrieved on: 
Thursday, March 31, 2022

RESEARCH TRIANGLE PARK, N.C., March 31, 2022 (GLOBE NEWSWIRE) -- Incyclix Bio, LLC (formerly Arc Therapeutics, LLC), a next-generation cell cycle control company, today announced the closing of a $30 million Series B financing led by new investor Boxer Capital. Additional new investor RA Capital Management also participated in the round, along with existing investor Eshelman Ventures. Sid Subramony, Ph.D., Vice President of Boxer Capital, will join the Company’s board of directors. Nathaniel Brooks Horwitz, Principal of RA Capital Management, will join Incyclix Bio as a board observer.

Key Points: 
  • Funds to support clinical development of INX-315, the companys lead Cyclin-Dependent Kinase 2 inhibitor
    RESEARCH TRIANGLE PARK, N.C., March 31, 2022 (GLOBE NEWSWIRE) -- Incyclix Bio, LLC (formerly Arc Therapeutics, LLC), a next-generation cell cycle control company, today announced the closing of a $30 million Series B financing led by new investor Boxer Capital.
  • Nathaniel Brooks Horwitz, Principal of RA Capital Management, will join Incyclix Bio as a board observer.
  • We are thrilled to welcome top-tier investors Boxer Capital and RA Capital who share our excitement and enthusiasm for the important work that Incyclix Bio has undertaken, said Fred Eshelman, Co-Founder and Chairman of the Board and founder of Eshelman Ventures LLC.
  • Incyclix Bio expects to initiate a proof-of-concept Phase 1/2 study of INX-315 in CDK4/6-resistant and Cyclin E-overexpressed cancers, including breast and ovarian cancer.

Serine/Threonine Protein Kinase Pim 2 Drug Market Research Report 2022: Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players - ResearchAndMarkets.com

Retrieved on: 
Friday, April 1, 2022

The "Serine/Threonine Protein Kinase Pim 2 (Pim 2h or Proto Oncogene Pim 2 or PIM2 or EC 2.7.11.1) Drugs In Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Serine/Threonine Protein Kinase Pim 2 (Pim 2h or Proto Oncogene Pim 2 or PIM2 or EC 2.7.11.1) Drugs In Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update" report has been added to ResearchAndMarkets.com's offering.
  • Serine/Threonine Protein Kinase Pim 2 pipeline Target constitutes close to 10 molecules.
  • Serine/Threonine Protein Kinase Pim 2 (Pim 2h or Proto Oncogene Pim 2 or PIM2 or EC 2.7.11.1) - Serine/threonine-protein kinase Pim-2 is an enzyme encoded by the PIM2.
  • It also reviews key players involved in Serine/Threonine Protein Kinase Pim 2 (Pim 2h or Proto Oncogene Pim 2 or PIM2 or EC 2.7.11.1) targeted therapeutics development with respective active and dormant or discontinued projects.

Aphios Granted US Patent For Combination HIV Latency Nanoparticles Towards an HIV Cure

Retrieved on: 
Tuesday, February 8, 2022

The Aphios 11,234,932 patent is part of a family of patents for a combination of two Latency Reversal Agents (LRAs) -- a Protein Kinase C (PKC) modulator of the anti-tumor class, ‘Bryoids’ and a Histone Deacetylase (HDAC) inhibitor co-encapsulated in long-circulating pegylated nanoparticles to purge latent HIV from cellular reservoirs. These patents are for the nanoparticles, medications, their manufacturing and uses. The two LRAs act synergistically. Bryostatin-1 activates, via a classical PKC pathway, transcription factors such as NF-κB that binds HIV-1 promoters and regulates their transcription, while the HDAC inhibitors increase histone acetylation, relaxing (opening) chromatin and facilitating the transcription of HIV-1 genes.

Key Points: 
  • Aphios Corporation announced today that it has been granted US Patent No.
  • 11,234,932 for treating HIV latency towards an HIV cure.
  • HIV, however, establishes latent long-term infection in a small pool of memory CD4+ T (immune) and other cells, which contain integrated but transcriptionally silent HIV provirus.
  • There are no commercially available drugs for treating HIV latency and/or curing HIV.

Mitogen Activated Protein Kinase Kinase (MEK or MAP2K) Inhibitor Drug Pipeline Market Report 2022 Featuring Bayer, Onyx Pharmaceuticals, Array BioPharma, Oncodesign Biotechnology, Atriva Therapeutics - ResearchAndMarkets.com

Retrieved on: 
Friday, February 4, 2022

The "Mitogen Activated Protein Kinase Kinase (MEK or MAP2K) Inhibitor - Pipeline Insight, 2022" clinical trials has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Mitogen Activated Protein Kinase Kinase (MEK or MAP2K) Inhibitor - Pipeline Insight, 2022" clinical trials has been added to ResearchAndMarkets.com's offering.
  • The report offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Mitogen Activated Protein Kinase Kinase (MEK or MAP2K) Inhibitor development.
  • The report assesses the active Mitogen Activated Protein Kinase Kinase (MEK or MAP2K) Inhibitor pipeline products by developmental stage, product type, molecule type, and administration route.
  • Offers detailed therapeutic product profiles of Mitogen Activated Protein Kinase Kinase (MEK or MAP2K) Inhibitor with key coverage of developmental activities including licensing & collaboration deals, patent details, designations, technologies, indications and chemical information
    Therapeutic assessment of the active pipeline products by stage, product type, molecule type, and route of administration